US 11,787,844 B2
Targeting of chondroitin sulfate glycans
Ali Salanti, Bronshoj (DK); Thor Grundtvig Theander, Greve (DK); Mads Daugaard, Vancouver (CA); Morten Nielsen, Birkerod (DK); Madeleine Dahlback, Swedala (SE); and Thomas Mandel Clausen, Copenhagen (DK)
Assigned to VAR2 Pharmaceuticals APS, Kobenhavn N (DK)
Appl. No. 14/376,295
Filed by VAR2 PHARMACEUTICALS APS, Copenhagen (DK)
PCT Filed Feb. 8, 2013, PCT No. PCT/EP2013/052557
§ 371(c)(1), (2) Date Aug. 1, 2014,
PCT Pub. No. WO2013/117705, PCT Pub. Date Aug. 15, 2013.
Claims priority of provisional application 61/596,931, filed on Feb. 9, 2012.
Prior Publication US 2015/0004099 A1, Jan. 1, 2015
Int. Cl. A61K 39/015 (2006.01); A61K 35/68 (2006.01); C07K 14/445 (2006.01); G01N 33/574 (2006.01); A61K 38/16 (2006.01); A61K 38/45 (2006.01); A61K 49/00 (2006.01); A61K 51/08 (2006.01); C07K 14/21 (2006.01); C07K 14/34 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/445 (2013.01) [A61K 35/68 (2013.01); A61K 38/16 (2013.01); A61K 38/45 (2013.01); A61K 39/015 (2013.01); A61K 49/00 (2013.01); A61K 49/0056 (2013.01); A61K 51/088 (2013.01); C07K 14/21 (2013.01); C07K 14/34 (2013.01); G01N 33/574 (2013.01); G01N 33/57484 (2013.01); A61K 38/00 (2013.01); C07K 2319/33 (2013.01); C12Y 204/02036 (2013.01); G01N 2333/47 (2013.01); G01N 2333/70585 (2013.01)] 13 Claims
 
1. A conjugate or a fusion protein comprising an isolated VAR2CSA polypeptide and a diagnostic effector moiety, wherein said VAR2CSA polypeptide comprises
a wild-type ID1-DBL2Xb sequence having at least 70% sequence identity to the full-length sequence set forth in SEQ ID NO: 1 and has the functional activity of binding to chondroitin sulfate A (CSA), or
a wild-type ID1-DBL2Xb sequence in the form of a functional fragment of SEQ ID NO: 1 that is between 570 and 640 amino acids in length, wherein the functional fragment has the functional activity of binding to CSA,
wherein said diagnostic effector moiety is a magnetic bead capable of being detected upon binding of said conjugate to CSA expressed on cancer cells.